Oral glucose tolerance testing in cystic fibrosis: correlations with clinical parameters and glycosylated haemoglobin determinations
- PMID: 2040347
- DOI: 10.1007/BF02093718
Oral glucose tolerance testing in cystic fibrosis: correlations with clinical parameters and glycosylated haemoglobin determinations
Abstract
In 48 patients (age 2-28 years) with documented cystic fibrosis, glucose tolerance was evaluated by means of an oral glucose tolerance test (OGTT) and repeated glycosylated haemoglobin (HbA1C) measurements. An impaired OGTT was found in 15 patients. Their degree of undernutrition and severity of lung and liver involvement were no different from those with normal glucose tolerance. The mean peak insulin concentration as well as the integrated insulin concentration during the OGTT were comparable with patients with normal glucose tolerance (GT) and those with an impaired tolerance (GI). The mean time to attain peak insulin levels was significantly delayed in the GI group. (117 min vs 86 min P less than 0.01). On initial testing, elevated HbA1C levels were found in 22 patients. Mean HbA1C levels in the GI group were higher than in the GT group (8.2% vs 7.5% P less than 0.01). The HbA1C levels at the moment of OGT testing were positively correlated with the glycaemic response during the OGTT. The repeated HbA1C measurements 1 year later were no different from the initial mean HbA1C values in both groups. Two GI patients with initial HbA1C levels of 7.5% and 11% respectively developed diabetes mellitus several months after testing. The need for serial HbA1C determinations in cystic fibrosis is questioned.
Similar articles
-
Time to replace the oral glucose tolerance test for cystic fibrosis related diabetes first-step screening? Establishing glycemic tools relevant to cystic fibrosis.Ann Med. 2025 Dec;57(1):2514787. doi: 10.1080/07853890.2025.2514787. Epub 2025 Jun 5. Ann Med. 2025. PMID: 40471094 Free PMC article.
-
Relationship between exercise capacity and glucose tolerance in cystic fibrosis.Pediatr Pulmonol. 2018 Feb;53(2):154-161. doi: 10.1002/ppul.23906. Epub 2017 Nov 8. Pediatr Pulmonol. 2018. PMID: 29115018
-
Early detection of impaired glucose tolerance in patients with cystic fibrosis and predisposition factors.J Pediatr Endocrinol Metab. 2001 Jan;14(1):53-60. doi: 10.1515/jpem.2001.14.1.53. J Pediatr Endocrinol Metab. 2001. PMID: 11220706
-
Glycated hemoglobin cannot yet be proposed as a screening tool for cystic fibrosis related diabetes.J Cyst Fibros. 2016 Mar;15(2):258-60. doi: 10.1016/j.jcf.2016.02.005. Epub 2016 Feb 19. J Cyst Fibros. 2016. PMID: 26905501 Review.
-
Cystic fibrosis related diabetes mellitus - diagnostic and management challenges.Curr Diabetes Rev. 2010 Jan;6(1):9-16. doi: 10.2174/157339910790442600. Curr Diabetes Rev. 2010. PMID: 20034372 Review.
Cited by
-
Reduced pancreatic insulin release and reduced peripheral insulin sensitivity contribute to hyperglycaemia in cystic fibrosis.Eur J Pediatr. 1995 May;154(5):356-61. Eur J Pediatr. 1995. PMID: 7641765
-
ISPAD Clinical Practice Consensus Guidelines 2022: Management of cystic fibrosis-related diabetes in children and adolescents.Pediatr Diabetes. 2022 Dec;23(8):1212-1228. doi: 10.1111/pedi.13453. Pediatr Diabetes. 2022. PMID: 36537525 Free PMC article. No abstract available.
References
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous